Modest Step-ups for Biotech's Private Investors
This article was originally published in Start Up
Executive Summary
Those venture capitalists with investments in the seven biotech companies that went public this year actually have reason for some degree of satisfaction: on average, they made pretty good money.
You may also be interested in...
Biotech's 2004 IPOs: Better Rewards for VCs?
The biotech IPO window cracked open slightly last year for seven companies with manageable step-ups-but will the market be more receptive in 2004 to firms seeking bigger windfalls?
Sobering Results So Far for Biotech's Private Investors
If venture capitalists were hoping to see a big profit, not merely liquidity, from a biotech IPO window, they've been seriously disappointed. Average step-up multiples for the seven biotech companies that went public in 2003 are quite low, especially compared to the heyday of 2000.
Which Private Investors are Cashing Out?
Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.